Tags

Type your tag names separated by a space and hit enter

Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases.
Sci Rep. 2021 04 21; 11(1):8589.SR

Abstract

The advancement in the processing speeds of computing machines has facilitated the development of complex physiologically based pharmacokinetic (PBPK) models. These PBPK models can incorporate disease-specific data and could be used to predict pharmacokinetics (PK) of administered drugs in different chronic conditions. The present study aimed to develop and evaluate PBPK drug-disease models for captopril after incorporating relevant pathophysiological changes occurring in adult chronic kidney disease (CKD) and chronic heart failure (CHF) populations. The population-based PBPK simulator Simcyp was used as a modeling and simulation platform. The visual predictive checks and mean observed/predicted ratios (ratio(Obs/pred)) of the PK parameters were used for model evaluation. The developed disease models were successful in predicting captopril PK in all three stages of CKD (mild, moderate, and severe) and CHF, as the observed and predicted PK profiles and the ratio(obs/pred) for the PK parameters were in close agreement. The developed captopril PBPK models can assist in tailoring captopril dosages in patients with different disease severity (CKD and CHF).

Authors+Show Affiliations

Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, 60800, Pakistan. fawadrasool@bzu.edu.pk.Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, 60800, Pakistan.Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, 60800, Pakistan.Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, 60800, Pakistan.Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, 60800, Pakistan.Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, 60800, Pakistan.University College of Pharmacy, Allama Iqbal Campus, University of the Punjab, Lahore, 54000, Pakistan.Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan.Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, 38000, Pakistan.Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia. Afaleh@ksu.edu.sa.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33883647

Citation

Rasool, Muhammad F., et al. "Development and Evaluation of Physiologically Based Pharmacokinetic Drug-disease Models for Predicting Captopril Pharmacokinetics in Chronic Diseases." Scientific Reports, vol. 11, no. 1, 2021, p. 8589.
Rasool MF, Ali S, Khalid S, et al. Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases. Sci Rep. 2021;11(1):8589.
Rasool, M. F., Ali, S., Khalid, S., Khalid, R., Majeed, A., Imran, I., Saeed, H., Usman, M., Ali, M., Alali, A. S., AlAsmari, A. F., Ali, N., Asiri, A. M., Alasmari, F., & Alqahtani, F. (2021). Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases. Scientific Reports, 11(1), 8589. https://doi.org/10.1038/s41598-021-88154-2
Rasool MF, et al. Development and Evaluation of Physiologically Based Pharmacokinetic Drug-disease Models for Predicting Captopril Pharmacokinetics in Chronic Diseases. Sci Rep. 2021 04 21;11(1):8589. PubMed PMID: 33883647.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases. AU - Rasool,Muhammad F, AU - Ali,Shazia, AU - Khalid,Sundus, AU - Khalid,Ramsha, AU - Majeed,Abdul, AU - Imran,Imran, AU - Saeed,Hamid, AU - Usman,Muhammad, AU - Ali,Mohsin, AU - Alali,Amer S, AU - AlAsmari,Abdullah F, AU - Ali,Nemat, AU - Asiri,Ali Mohammed, AU - Alasmari,Fawaz, AU - Alqahtani,Faleh, Y1 - 2021/04/21/ PY - 2020/11/30/received PY - 2021/04/08/accepted PY - 2021/4/22/entrez PY - 2021/4/23/pubmed PY - 2021/11/16/medline SP - 8589 EP - 8589 JF - Scientific reports JO - Sci Rep VL - 11 IS - 1 N2 - The advancement in the processing speeds of computing machines has facilitated the development of complex physiologically based pharmacokinetic (PBPK) models. These PBPK models can incorporate disease-specific data and could be used to predict pharmacokinetics (PK) of administered drugs in different chronic conditions. The present study aimed to develop and evaluate PBPK drug-disease models for captopril after incorporating relevant pathophysiological changes occurring in adult chronic kidney disease (CKD) and chronic heart failure (CHF) populations. The population-based PBPK simulator Simcyp was used as a modeling and simulation platform. The visual predictive checks and mean observed/predicted ratios (ratio(Obs/pred)) of the PK parameters were used for model evaluation. The developed disease models were successful in predicting captopril PK in all three stages of CKD (mild, moderate, and severe) and CHF, as the observed and predicted PK profiles and the ratio(obs/pred) for the PK parameters were in close agreement. The developed captopril PBPK models can assist in tailoring captopril dosages in patients with different disease severity (CKD and CHF). SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/33883647/Development_and_evaluation_of_physiologically_based_pharmacokinetic_drug_disease_models_for_predicting_captopril_pharmacokinetics_in_chronic_diseases_ DB - PRIME DP - Unbound Medicine ER -